AstraZeneca pushes back OS readout on MYSTIC to H2; Anthera shares obliterated in repeat PhIII flop
→ The much-anticipated overall survival data of AstraZeneca’s $AZN pivotal lung cancer trial will be delivered later than expected, the UK drugmaker announced this morning. Investors will now have to wait until the second half of 2018 for the final analysis of Imfinzi’s impact on OS, instead of the first half. The results from the MYSTIC trial remains a major catalyst after the checkpoint inhibitor failed to meet the primary endpoint of progression-free survival (PFS), sending a shock wave to AstraZeneca’s stock prices last July. The trial tests Imfinzi both as a monotherapy and in combination with tremelimumab against chemotherapy in first-line non-small cell lung cancer, an all-important arena in the battle for checkpoint drug dominance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.